Akorn’s data integrity issues are normal, consultant testifies

The data integrity issues that Akorn is dealing with – but that prompted Fresenius to abandon its purchase of the generic drugmaker – are common across the industry, a consultant has testified at the Delaware Court of Chancery.

Get unlimited access to all Global Competition Review content